The Quarter story
The two most recent quarterly results, compared side-by-side.
Supriya Lifescience drives top-line growth and expands in Asia and LATAM, but rising operational costs compress profitability margins.
Finance costs fall from ₹5.1 Cr to ₹3.7 Cr from Q1 FY26 to Q1 FY27 — lower borrowing costs ease cash flow pressure
EBITDA margin falls from 35.6% to 25.0% from Q1 FY26 to Q1 FY27 — input costs or pricing pressure squeezes operating profits
Asia revenue contribution rises from 32% to 39% from Q1 FY26 to Q1 FY27 — stronger regional demand offsets other market dips
PAT margin drops from 24.0% to 12.7% from Q1 FY26 to Q1 FY27 — higher expenses directly impact net profitability
LATAM revenue contribution grows from 17% to 20% from Q1 FY26 to Q1 FY27 — expanding footprint in emerging economies
Other expenses rise from ₹389.1 Cr to ₹574.1 Cr from Q1 FY26 to Q1 FY27 — rising operational overheads strain efficiency
Revenue expands from ₹1,450.7 Cr to ₹1,897.5 Cr from Q1 FY26 to Q1 FY27 — consistent top-line growth despite seasonal fluctuations
Employee benefits expense increases from ₹226.9 Cr to ₹284.9 Cr from Q1 FY26 to Q1 FY27 — growing workforce costs add to the bottom line
Europe revenue contribution declines from 41% to 35% from Q1 FY26 to Q1 FY27 — shifting sales mix away from traditional markets
NSE
BSE
